Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedAug 26, 2025
DataAggregated Company Financials
Companies549
  • 7D-1.6%
  • 3M8.7%
  • 1Y-10.3%
  • YTD4.0%

Over the last 7 days, the Biotech industry has dropped 1.6%, driven by Gilead Sciences declining 3.3%. However, the industry is down 10% over the past year. Earnings are forecast to grow by 26% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 26 Aug 2025US$1.1tUS$163.6b-US$18,607,464,334.9015.2x-57.7x6.6x
Thu, 24 Jul 2025US$979.1bUS$155.2b-US$23,256,073,043.1517x-42.1x6.3x
Sat, 21 Jun 2025US$930.4bUS$155.9b-US$23,931,619,289.3716.8x-38.9x6x
Mon, 19 May 2025US$895.2bUS$155.9b-US$24,392,718,921.6016.3x-36.7x5.7x
Wed, 16 Apr 2025US$764.9bUS$119.2b-US$36,605,024,519.5620.2x-20.9x6.4x
Fri, 14 Mar 2025US$841.0bUS$118.5b-US$37,519,343,472.2717.8x-22.4x7.1x
Sun, 09 Feb 2025US$840.3bUS$117.3b-US$30,891,273,158.0417.2x-27.2x7.2x
Tue, 07 Jan 2025US$968.2bUS$149.6b-US$26,363,916,330.8816.7x-36.7x6.5x
Thu, 05 Dec 2024US$1.0tUS$150.0b-US$26,559,447,157.6617.4x-38.6x6.8x
Sat, 02 Nov 2024US$1.1tUS$147.4b-US$30,526,626,860.5217.5x-34.7x7.2x
Mon, 30 Sep 2024US$893.6bUS$113.2b-US$36,006,680,210.7121.3x-24.8x7.9x
Wed, 28 Aug 2024US$912.3bUS$113.2b-US$35,873,175,029.8023.7x-25.4x8.1x
Fri, 26 Jul 2024US$1.2tUS$164.3b-US$28,279,434,472.0928.4x-42.8x7.4x
Sun, 23 Jun 2024US$1.2tUS$164.4b-US$27,942,490,934.1228.1x-41.4x7x
Tue, 21 May 2024US$1.1tUS$164.6b-US$26,833,016,716.7724.2x-42.8x7x
Thu, 18 Apr 2024US$1.1tUS$164.2b-US$23,335,767,618.8220.4x-46.2x6.6x
Sat, 16 Mar 2024US$1.2tUS$167.4b-US$22,091,319,843.2913.9x-53.3x7x
Mon, 12 Feb 2024US$1.2tUS$169.3b-US$26,263,046,791.8719.8x-44.2x6.9x
Wed, 10 Jan 2024US$1.4tUS$204.8b-US$22,502,246,114.0020.4x-64.2x7.1x
Fri, 08 Dec 2023US$1.3tUS$204.6b-US$22,051,399,456.0019.3x-58.1x6.3x
Sun, 05 Nov 2023US$1.2tUS$206.7b-US$20,535,513,316.0018.8x-60.4x6x
Tue, 03 Oct 2023US$1.3tUS$207.3b-US$13,085,561,707.0016.8x-96x6.1x
Thu, 31 Aug 2023US$1.3tUS$207.7b-US$12,462,393,654.0017.6x-103.8x6.2x
Sat, 29 Jul 2023US$1.1tUS$186.0b-US$15,177,418,533.0014.7x-74.9x6.1x
Mon, 26 Jun 2023US$1.1tUS$186.2b-US$16,162,116,001.0013.6x-70.3x6.1x
Wed, 24 May 2023US$1.2tUS$186.1b-US$15,836,040,128.0012.9x-73.2x6.2x
Fri, 21 Apr 2023US$1.2tUS$198.4b-US$3,235,324,680.0013.6x-364.2x5.9x
Sun, 19 Mar 2023US$1.1tUS$199.2b-US$3,885,938,113.0013.2x-287.6x5.6x
Tue, 14 Feb 2023US$1.2tUS$202.8b-US$239,371,196.0016.5x-4869.1x5.7x
Thu, 12 Jan 2023US$1.2tUS$203.6bUS$1.7b14.3x687.1x5.7x
Sat, 10 Dec 2022US$1.1tUS$202.7bUS$1.4b14.6x811.3x5.6x
Mon, 07 Nov 2022US$1.1tUS$204.3bUS$3.8b13.4x285.1x5.3x
Wed, 05 Oct 2022US$1.1tUS$206.5bUS$5.6b15.6x189.7x5.2x
Fri, 02 Sep 2022US$1.1tUS$206.1bUS$7.2b15.3x147.2x5.1x
Price to Earnings Ratio

147.2x


Total Market Cap: US$1.1tTotal Earnings: US$7.2bTotal Revenue: US$206.1bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average 40x202320242025
Current Industry PE
  • Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 6.4x.
Past Earnings Growth
  • Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
  • Revenues have also declined 7.4% per year, which is driving profits down.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.19%
Healthcare-0.34%
Biotech-1.63%
Biotech-1.63%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ABBV AbbVieUS$207.550.7%
+US$2.4b		5.9%PE98.5x
CAI Caris Life SciencesUS$38.487.0%
+US$711.5m		n/aPS20.3x
MDGL Madrigal PharmaceuticalsUS$412.235.3%
+US$463.6m		61.2%PS17.8x
MENS Jyong BiotechUS$47.0013.3%
+US$408.3m		n/aPE-1155.7x
HALO Halozyme TherapeuticsUS$72.214.7%
+US$380.1m		16.2%PE15.2x

Latest News

ETHZ
US$3.08
ETHZilla
7D
-58.5%
1Y
56.9%
INSM
US$128.32
Insmed
7D
0.9%
1Y
66.4%

Brensocatib's 2025 Launch Will Transform Bronchiectasis Care

Insmed’s consensus price target has surged to $148.44, driven by the FDA approval and strong commercial prospects for Brinsupri, expanded pipeline potential, and robust Phase 2 results for TPIP—underscoring significant upward revisions in revenue and profit expectations. Analyst Commentary Bullish analysts are raising price targets following FDA approval of Brinsupri as the first therapy for non-cystic fibrosis bronchiectasis, citing a broad label with both doses approved, clean safety profile, and inclusion of favorable FEV1 and secondary endpoint data in prescribing information.
MDGL
US$412.23
Madrigal Pharmaceuticals
7D
5.3%
1Y
61.2%

Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) 30% Price Boost Is Out Of Tune With Revenues

Aug 22
Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) 30% Price Boost Is Out Of Tune With Revenues
ALNY
US$443.64
Alnylam Pharmaceuticals
7D
-2.9%
1Y
64.8%
ABBV
US$207.55
AbbVie
7D
0.7%
1Y
5.9%
ONC
US$308.63
BeOne Medicines
7D
-3.3%
1Y
54.9%
HALO
US$72.21
Halozyme Therapeutics
7D
4.7%
1Y
16.2%

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Rockets 27% But Many Are Still Ignoring The Company

Aug 21
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Rockets 27% But Many Are Still Ignoring The Company
VKTX
US$25.85
Viking Therapeutics
7D
-38.6%
1Y
-60.5%
PGEN
US$3.98
Precigen
7D
34.9%
1Y
246.1%
BNTX
US$105.07
BioNTech
7D
-6.6%
1Y
20.1%
GILD
US$114.15
Gilead Sciences
7D
-3.3%
1Y
48.3%
CAI
US$38.48
Caris Life Sciences
7D
7.0%
1Y
n/a
AMGN
US$288.47
Amgen
7D
-1.4%
1Y
-11.7%

Statutory Profit Doesn't Reflect How Good Amgen's (NASDAQ:AMGN) Earnings Are

Aug 13
Statutory Profit Doesn't Reflect How Good Amgen's (NASDAQ:AMGN) Earnings Are
MIRM
US$71.81
Mirum Pharmaceuticals
7D
7.7%
1Y
66.7%

Genetic Testing And International Expansion Will Broaden Rare Disease Markets

Mirum Pharmaceuticals’ modest target price increase reflects improved consensus revenue growth forecasts, though this is partially offset by a slight expansion in the future P/E multiple, resulting in a marginal upward revision of the fair value to $77.20. What's in the News Mirum Pharmaceuticals raised its 2025 revenue guidance to $490 million to $510 million.
MRNA
US$25.35
Moderna
7D
-9.8%
1Y
-69.0%